article thumbnail

STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more

STAT

Keytruda is a cancer immunotherapy, which stimulates the immune system to attack tumor cells and is the best-selling medicine in the world. patent expires in 2028. The subcutaneous injection could be given in a doctor’s office every six weeks, instead of requiring a 30-minute IV drip at the same interval.

article thumbnail

Merck’s latest deal turns up the spotlight on immune system drugmakers

BioPharma Dive

The buyout of Prometheus highlights pharmaceutical companies’ intense interest in medicines targeting inflammatory diseases, according to analysts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Tetra and Cellvera partner to develop oral Covid-19 treatment

Pharmaceutical Technology

It is claimed to have outperformed an antiviral drug in lowering various proinflammatory mediators linked to hyperinflammation and dysfunction of the immune system after viral infection. Qifenda is a broad-spectrum antiviral drug in the commercial stage. Developed by FujiFilm Toyama Chemical, Favipiravir is currently owned by Cellvera.

Immunity 132
article thumbnail

Boehringer Ingelheim to lay off staff amid biosimilar challenges

BioPharma Dive

The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

article thumbnail

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

article thumbnail

Innovation in immuno-oncology: Leading companies in cancer monoclonal antibody therapy

Pharmaceutical Technology

Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).

Immunity 104
article thumbnail

Povetacicept by Alpine Immune Sciences for Systemic Lupus Erythematosus: Likelihood of Approval

Pharmaceutical Technology

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The drug candidate is an engineered B-cell modulator.